Clinical and Translational Oncology

, Volume 7, Issue 7, pp 314–320 | Cite as

Radioquimioterapia de la enfermedad limitada del carcinoma pulmonar de célula pequeña. ¿Tratamiento concomitante en protocolos asistenciales?

  • Ana Lucas Calduch
  • María Dolores Arnaiz Fernández
  • Sol San José Maderuelo
  • Valentí Navarro Pérez
  • Gala Serrano Bermúdez
  • Ana Montes Borinaga
  • Felipe Cardenal Alemany
  • Branislav Jeremic
  • Ferran Guedea Edo
Original Articles

Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols?



We retrospectively reviewed our institution’s database to investigate the outcome and impact of combined radiochemotherapy (RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC).

Material and methods

Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at our Institution. RT was delivered concurrently or sequentially following the CT. Patients with treatment response received additional prophylactic cranial irradiation (PCI).


Of the patients treated, 54% had received concurrent CT/RT compared to 46% receiving RT following the CT. PCI was administered to 80% of the patients. Complete response was observed in 66% of patients. With a median follow up of 30 months, median overall survival was 15.9 months; 14.3 months for patients who received RT following CT and 21.6 months for those receiving concurrent CT/RT. The type of schedule of combined radiochemotherapy was an independent prognostic factor for survival free of local recurrence, as was additional PCI for distant metastasis-free survival.


Our results are similar to those reported previously in the literature. The main point of interest is that our patients were non-selected. We strongly support the use of concurrent CT/RT so as to achieve results comparable to the best in the literature.

Key words

lung cancer small cell localised disease radiotherapy chemotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer satistics 2000. Cancer J Clin. 2001;50:7–33.CrossRefGoogle Scholar
  2. 2.
    Warde P, Payne D. Does radiotherapy radiation improve survival and local control in limited-stage small cell carcinoma of the lung? J Clinc, Oncol. 1992;10:890–5.Google Scholar
  3. 3.
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Albain KS, Crowley JJ, LeBlane M, Livingston RB. Determinants of improved outcome in small cell lung cancer: an analysis of the 2580-patient Southwest Oncology Group data base. J Clin Oncol. 1990;8:1563–74.PubMedGoogle Scholar
  5. 5.
    Arriagada R, Kramar A, Le Chevalier T, De Cremoux H. Competing events determining relapse-free survival in limited small-cell lung carcinoma. J Clin Oncol. 1992; 10:447–51.PubMedGoogle Scholar
  6. 6.
    Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently cisplatin and etoposide. N Engl J Med. 1999;340:265–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Auperin A, Arriagada R, Pignon JP, et al. Prophilactic cranial irradiation for patients with small cell lung cancer in complete remision. N Engl J Med. 1999;341:476–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Green, RA, Humprey E, Close H, Patno ME. Alkilating agents in bronchogenic carcinoma. Am J Med. 1969; 46:516–25.PubMedCrossRefGoogle Scholar
  9. 9.
    International Comission on Radiological Units and Measurements. Prescribing, recording and reporting photon beam therapy. ICRU Report No 50; 1993.Google Scholar
  10. 10.
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Cancer Therapy Evaluation Program. Common toxicity Criteria, version 2.0. Bethesda, USA; 1999.Google Scholar
  12. 12.
    Borràs JM, Fernández E, Schiaffino A, Borrell C, La Vecchia C. Pattern of smoking iniciation in Catalonia, Spain, from 1948 to 1991. Am J Public Health. 2000; 90:1459–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Borràs J, Borràs JM, Galcerán J, Sánchez V, Moreno V, González JR. Trends in smoking-related cancer incidence in Tarragona, Spain, 1980–1996. Cancer Causes Control. 2001;12:903–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Sierocki JS, Hilaris BS, Hopfan S, et al. Cis-dichloro-diammineplatinum (II) and VP-16-213: an active regimen for small cell carcinoma of the lung. Cancer Treat Rep. 1979;63:1593–8.PubMedGoogle Scholar
  15. 15.
    Bunn PA, Cullen M, Fukuoka M, et al. Chemotherapy in small cell lung cancer: a consensus report. Lung Cancer. 1989;5:127–34.CrossRefGoogle Scholar
  16. 16.
    Goldie JG, Coldman AJ. A mathematical model for relating the drug sensivity of tumours to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–35.PubMedGoogle Scholar
  17. 17.
    Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer. J Clin Oncol. 1997;15:893–900.PubMedGoogle Scholar
  18. 18.
    Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group study 9104. J Clin Oncol. 2002; 20:3054–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 1987;316:912–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Work E, Nielsen O, Bentzen S, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer. J Clin Oncol. 1997;15:3030–7.PubMedGoogle Scholar

Copyright information

© FESEO 2005

Authors and Affiliations

  • Ana Lucas Calduch
    • 3
  • María Dolores Arnaiz Fernández
    • 3
  • Sol San José Maderuelo
    • 3
  • Valentí Navarro Pérez
    • 3
  • Gala Serrano Bermúdez
    • 3
  • Ana Montes Borinaga
    • 1
  • Felipe Cardenal Alemany
    • 1
  • Branislav Jeremic
    • 2
  • Ferran Guedea Edo
    • 3
  1. 1.Servicio de Oncología MédicaInstitut Català d'OncologíaBarcelonaEspaña
  2. 2.Servicio de Oncología Radioterápica. Klinikum rechts der IsarTechnical UniversityMunichAlemania
  3. 3.Servicio de Oncología RadioterápicaInstitut Català d'OncologiaL'Hospitalet. Barcelona

Personalised recommendations